Pigmentary changes in chronic myeloid leukemia patients treated with imatinib mesylate.
Arora
B
B
Kumar
L
L
Sharma
A
A
Wadhwa
J
J
Kochupillai
V
V
D000970:Antineoplastic Agents / Q000009:adverse effects* / Q000627:therapeutic use*; D001549:Benzamides; D005076:Exanthema / Q000139:chemically induced; D006801:Humans; D000068877:Imatinib Mesylate; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy*; D010859:Pigmentation Disorders / Q000139:chemically induced* / Q000503:physiopathology; D010879:Piperazines / Q000009:adverse effects* / Q000627:therapeutic use*; D011743:Pyrimidines / Q000009:adverse effects* / Q000627:therapeutic use*
D000970:Antineoplastic Agents; D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate